Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07832292) titled 'A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer' on Sept. 16.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Janssen Research & Development, LLC
Condition:
Prostatic Neoplasms
Intervention:
Drug: JNJ-101556143
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 28, 2026
Target Sample Size: 100
To know more, visit https://clinicaltrials.gov/study/NCT07832292
Published by HT Digital Content Services with permission fr...